BioCryst Pharmaceuticals Reports Q3 2026 Earnings: EPS of $0.14 and Revenue of $180. ...
ORLADEYO Franchise Expansion and CareMed Transition Drive Profitability; Full-Year Revenue Guidance Raised Related Stocks: BCRX ,
ORLADEYO Franchise Expansion and CareMed Transition Drive Profitability; Full-Year Revenue Guidance Raised Related Stocks: BCRX ,